Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE AND STAVUDINE versus LAMIVUDINE NEVIRAPINE AND ZIDOVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE AND STAVUDINE versus LAMIVUDINE NEVIRAPINE AND ZIDOVUDINE.
LAMIVUDINE, NEVIRAPINE, AND STAVUDINE vs LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine and stavudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by incorporating into viral DNA and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing a conformational change and inhibiting its activity.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural nucleosides and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and inhibits RNA-dependent DNA polymerase activity.
Lamivudine 150 mg, nevirapine 200 mg, and stavudine 30 mg (or 40 mg if weight ≥60 kg) orally twice daily for HIV treatment in adults.
One tablet (lamivudine 150 mg, nevirapine 200 mg, zidovudine 300 mg) orally twice daily.
None Documented
None Documented
Lamivudine: 5-7 hours (prolonged in renal impairment). Nevirapine: 25-30 hours (terminal, autoinduction reduces early half-life; significant accumulation). Stavudine: 1.0-1.6 hours (short; prolonged in renal impairment).
Lamivudine: 5-7 hours; Nevirapine: 25-30 hours (single dose), 40-45 hours with multiple dosing due to autoinduction; Zidovudine: 0.5-3 hours (mean 1.1 hours). Clinical context: Dosing interval adjusted for renal/hepatic function.
Lamivudine: ~71% excreted unchanged in urine (glomerular filtration and active tubular secretion). Nevirapine: ~81% excreted in urine as glucuronide conjugates, <5% unchanged; ~10% in feces. Stavudine: ~40% excreted unchanged in urine (active tubular secretion), with remainder as metabolites.
Lamivudine: >70% unchanged in urine via glomerular filtration and active tubular secretion. Nevirapine: ~80% in urine as glucuronide conjugates and metabolites, <5% unchanged. Zidovudine: ~75% as metabolites (primarily zidovudine glucuronide) in urine, <20% unchanged.
Category A/B
Category A/B
NRTI
NRTI